Genflow Biosciences Share Discussion Threads

[moneymunch] 17/5/2024 06:22

The Business Case for Longevity

·May 2024 ·

Longevity is the biggest market in the world.

The ROI is huge, almost too big to see. Many people also don’t realize that longevity businesses are critical for the future of humanity.

Imagine not being resigned to growing old, frail and sick. Imagine being able to extend your peak earning years. Imagine being able to delay having kids safely (if you choose!) to allow yourself more time to pursue a career. People could have second or third careers. People could invest their money over longer periods of time, accumulating more wealth. People could have the opportunity to actually enjoy that wealth before they die.

If we can extend the human healthspan, it will not just save tons of money (think of all the money dedicated to playing whack-a-mole with age-related diseases). It will also make almost every other industry bigger.

From a business perspective, this all increases the “L” in LTV (lifetime value of customers). More people living longer, more fulfilled lives has the potential to increase returns across many industries, and will probably create new ones over time. The TAM for Longevity is everyone.

Society has a choice: spend trillions on early death, or make trillions in longer life.

Reason 1: The Market is Everyone

Drug companies make money when there’s a lot of demand for their drug (lots of sick people), or there are limited treatment options available (only drug in town). But the best bet is to go for the big market. As a result, most of the blockbusters come from pursuing diseases that affect nearly everyone eventually.

For example, the top ten leading causes of death in the US are:

Heart Disease
Cancer
Accidents
Cerebrovascular disease
Chronic lower respiratory disease
Alzheimer’s
Diabetes
Kidney Disease
Liver Disease
COVID-19

In turn, some of the top-selling drugs include:

Lipitor, one of the best selling drugs of all time, is a cholesterol drug intended to help prevent heart disease – the #1 cause of death in the US.

Keytruda, for treating multiple cancers, is projected to be the 2nd best selling drug by 2028.

GLP-1 Drugs, like Ozempic, which treat both diabetes and aid with weight loss (a risk factor for many of these causes of death) are projected to be among the best sellers of all time.

Addressing just one of the leading causes of death in the US is enough to make a blockbuster drug. Addressing all of them at once is the biggest blockbuster of all time. And that’s what longevity medicines can do.

When we break down the top ten cases of death, you can see that aging is a primary risk factor for most of them. Between the ages of 1 and 44, the thing most likely to kill you is an unintentional injury (wear your seat belts). But past that point, heart disease, cancer, and COVID are the biggest threats. (Remember COVID is typically harmless to younger people, but is dangerous for people over 45).

Treating aging would be like addressing the heart disease, COVID, cancer, and diabetes markets all at once. It’s like a prophylactic for dying from preventable causes. And who wouldn’t like to take that drug? Nobody.

That’s mega-blockbuster potential.

[northeast14] 17/5/2024 06:17

Would be great to see another rise today. Big positions still being taking. Free float is dry. Rerate happening

[moneymunch] 16/5/2024 20:25

Genflow's collaborative partner for the delivery of SIRT6 and key to advancing the GMP manufacturing of its lead drug candidate. Gla :-)

18/4/24

"EXO Biologics recently created ExoXpert as an exosome CDMO to meet the demand for specialized GMP grade exosome manufacturing services internationally. As a therapeutic exosome developer, this was something EXO Biologics needed, but we also realized the international market needed this as well," said Hugues Wallemacq, CEO, ExoXpert and EXO Biologics. "ExoXpert has started working with a significant number of international cell and gene therapy developers that need a combination of exosome manufacturing and knowledge to develop new products for the benefit of patients. Partnering with Neucore will enable ExoXpert to further extend ExoXpert’s expertise in loading exosomes to Neucore’s FiXE platform.”

[moneymunch] 16/5/2024 20:16

7/5/24

Outlook for 2024



Our key objectives for 2024 are:



· Continuing to identify suitable grant funding to support the Group's project pipeline.

· Undertake key Investigational New Drug (IND)-enabling development activities that will help define the pharmacological and toxicological properties of our lead drug candidate, GF-1002, and its potential benefits for MASH patients.

· Select site and QMS framework for clinical readiness, expected by the end of 2025 for the MASH program.

· Commence preliminary discussions with the European Medicines Agency (EMA) on Mechanism of Action (MoA) data for Orphan Drug Application (ODA) for our second compound GF-3001, targeting Werner Syndrome.

· Select Contract Development and Manufacturing Organization (CDMO) for advancing the GMP manufacturing of the MASH clinical lot of lead drug candidate, GF-1002.

· Develop and implement project management, budgeting and governance for collaborative partners, in line with clinical and pre-clinal activities that will enable IND applications.

· Move key patent applications under the Patent Cooperation Treaty (PCT) to the national phase, while further expanding our development pipeline with new products and new indications.

[steg] 16/5/2024 18:24

Must be news coming, certainly lots of big news that could drop at any time 👍🙏👍

[northeast14] 16/5/2024 17:10

Great day!

[moneymunch] 16/5/2024 15:48

We could open above 2.4p at this rate. Gla holders...Excitement building;-)))

[cyberbub] 16/5/2024 15:44

Encouraging action late-on, but I won't be getting excited until we close above 2.4p... GLA

[moneymunch] 16/5/2024 14:54

Got a feeling the free float has been mopped UP!!! :-)

[moneymunch] 16/5/2024 14:46

Good news could drop at anytime to add significant value, but "The first payment of €777,000 from the 2.89m Euros grant is due to be received imminently" as stated in last week's results and confirmed in today's LinkedIn post...and so confirmation should be very well received. Gla...On and UP!!!:-)

[moneymunch] 16/5/2024 14:37

Genflow Biosciences (LON:GENF) (OTCQB:GENFF)

1,606 followers
3h

The #biotech space has continued to out perform expectations. As the industry is teetering on another market rally, many companies have had exciting developments.

Regeneron, for one, has announced it successfully restored the hearing of two children experiencing otoferlin hearing loss.

Additionally, Genflow Biosciences (LON:GENF) (OTCQB:GENFF) has secured several significant grants, some of whose payment is expected imminently. These will help advance its #sarcopenia & #mRNA delivery research.

Learn about Genflow's exciting investment proposition:

#pharma #aging #GENF

[moneymunch] 15/5/2024 21:34

Ditto Northeast, the free float is getting tighter and tighter and so every chance of a decent move North as more buyers arrive in anticipation of the next UPdate or two. Gl :-)

[northeast14] 15/5/2024 19:39

Money, the endless cheap shares can’t go on for ever. Looking forward to seeing more movement very soon

[moneymunch] 15/5/2024 08:05

Momentum building with the majority of shares very tightly held!!! Gla holders...On and UP!!! :-)

[moneymunch] 14/5/2024 19:38

Genflow Biosciences (LON:GENF) (OTCQB:GENFF)
1,604 followers

8h

The #biotech space is cluttered with many companies claiming to be on the cutting edge, with little to back this up. Genflow Biosciences (LON:GENF) (OTCQB:GENFF), on the other hand, stands out in numerous ways.

Differentiating between the true innovators and the rest can be difficult. That's why we've created a new fact sheet summarizing our exciting research that aims to extend both human and canine #healthspan.

What sets #GENF apart:
✅ Long life IP, protecting our #SIRT6 cenenarian gene & gene delivery research
✅ Creating #NASH treatment to address untapped market of 35 million people
✅ Lead by experienced team with a background running public companies

Learn more about Genflow's exciting investment thesis:

[northeast14] 14/5/2024 15:40

Hopefully the unjustified drop is over with now. Someone was very lucky with some cheap shares.

[felchandbart] 14/5/2024 14:56

This has certainly required some patience but it looks as though things are starting to get under way at last. Interest appears to be building. GLA

[steg] 14/5/2024 14:16

Bid jumped to 1.95 with no buys showing to justify….yet 👍

[moneymunch] 14/5/2024 13:53

Another 1m plus mopped UP!!! Gla :-)

[moneymunch] 14/5/2024 10:10

Lol, a pause in proceedings, £25k plus bought yesterday, £30k Friday, £40k Thursday along with confirmation Mr Swann is accumulating more and he's not the only one who is planning to buy more I reckon. Gl :

[cyberbub] 14/5/2024 09:32

GBP200 traded this morning so far...

[moneymunch] 14/5/2024 06:47

Anytime soon Northeast, although I'd prefer the share price to be firmly above 2p and more before the next UPdate arrives, which will be more than likely in the coming days as the share accumulation continues. Gl :-)

[northeast14] 14/5/2024 06:29

Was hoping for an update. Hopefully there is one soon

[moneymunch] 13/5/2024 10:05

A 1m buy just been filled. Gla :-)

[moneymunch] 10/5/2024 19:52

Looks like a 2m plus late reported buy imho...Gla ;-)